Medications

FDA approves Litfulo for teens, adults with alopecia areata

The U.S. Food and Drug Administration has approved Litfulo (ritlecitinib) for adults and adolescents aged 12 years and older with severe alopecia areata at a recommended dose of 50 mg. Approval of Litfulo was granted to Pfizer.

Genetics

Team identifies IL-17 protein as key factor in skin aging

A team of scientists from the Institute for Research in Biomedicine (IRB Barcelona) in collaboration with the National Center for Genomic Analysis (CNAG) has discovered that IL-17 protein plays a central role in skin aging. ...

page 7 from 40